Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 5/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9099876 | 0.94 | NAAA (0.47) | ALDH1A1ATMTSHRHCAR2NAAA | |
| SCHEMBL5982047 | 0.92 | NAAA (0.50) | ALDH1A1TSHRHCAR2NAAARAD52 | |
| SCHEMBL9099420 | 0.92 | NAAA (0.50) | ALDH1A1TSHRHCAR2NAAARAD52 | |
| SCHEMBL1864794 | 0.92 | NAAA (0.50) | ALDH1A1TSHRHCAR2NAAARAD52 | |
| SCHEMBL8090435 | 0.88 | CHRNB2 (0.41) | ALDH1A1ATMTSHRHCAR2TDP1 | |
| SCHEMBL8908162 | 0.79 | CHRNB2 (0.58) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| SCHEMBL295773 | 0.79 | — | — | |
| SCHEMBL10918173 | 0.75 | ALDH1A1 (0.52) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| SCHEMBL288939 | 0.75 | ALDH1A1 (0.52) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| SCHEMBL28046263 | 0.75 | ALDH1A1 (0.52) | ALDH1A1ATMTSHRHPGDHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160166526-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20150203464-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-23 | — | — | US | disclosed |
| US-20150051256-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-19 | — | — | US | disclosed |
| US-8901171-B2 | Compounds for suppressing a peripheral nerve disorder induced by an anti-cancer agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-02 | — | — | US | disclosed |
| US-20130345304-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-12-26 | — | — | US | disclosed |
| US-20130046000-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2013-02-21 | — | — | US | disclosed |
| US-RE43858-E1 | Substituted cycloalkene derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-12-11 | — | — | US | disclosed |
| EP-2528598-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI - CANCER AGENT | Takeda Pharmaceutical Company Limited (JP) | 2012-12-05 | — | — | EP | disclosed |
| US-20120077856-A1 | PHARMACEUTICAL PRODUCT | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-03-29 | — | — | US | disclosed |
| EP-2366389-A1 | Severe sepsis preventive therapeutic agent | Takeda Pharmaceutical Company Limited (JP) | 2011-09-21 | — | — | EP | disclosed |
| US-5155113-A | Administering 5-fluorouracil and derivatives with pyridine and pyridone derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-10-13 | — | — | US | disclosed |
| US-5047521-A | Anticarcinogenic agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-09-10 | — | — | US | disclosed |
| EP-0436902-A1 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-07-17 | — | — | EP | disclosed |
| US-4983609-A | Anticancer agents | OTSUKA PHARMACEUTICAL (JP) | 1991-01-08 | — | — | US | disclosed |
| US-4864021-A | ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-09-05 | — | — | US | disclosed |
| EP-0323441-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-07-05 | — | — | EP | disclosed |
| EP-0247381-A2 | 5-flurorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-12-02 | — | — | EP | disclosed |
| EP-0180897-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-14 | — | — | EP | disclosed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | disclosed |
| US-4139390-A | Presensitized printing plate having a print-out image | EASTMAN KODAK COMPANY (US) | 1979-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345304-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | PMP22, GAP43, NGF | ALDH1A1 2141/4885ATM 2903/4885TSHR 4293/4885 |
| US-20150203464-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | PMP22, GAP43, NGF | ALDH1A1 2141/4885ATM 2903/4885TSHR 4293/4885 |
| US-20130046000-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | PMP22, GAP43, NGF | ALDH1A1 2141/4885ATM 2903/4885TSHR 4293/4885 |
| US-20160166526-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | PMP22, GAP43, NGF | ALDH1A1 2141/4885ATM 2903/4885TSHR 4293/4885 |
| US-20120077856-A1 | PHARMACEUTICAL PRODUCT | ATF1, ATF4, TLR8 | ALDH1A1 939/4885ATM 1562/4885TSHR 3079/4885 |
| US-20150051256-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | PMP22, GAP43, NGF | ALDH1A1 2141/4885ATM 2903/4885TSHR 4293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.